Market Place
Sourcing Support
Jubilant Radiopharma & Simplified Imaging Announce Partnership
30 Oct 2024 //
BUSINESSWIRE
Jubilant announces first patient dosing in global clinical trials
25 Oct 2024 //
FINANCIALXPRESS
JBI-802 initial Phase I data suggests potential in sensitizing immunotherapy resistant tumors
08 Jan 2024 //
PR NEWSWIRE
Jubilant Appoints Nadir Patel as an Independent Member of Its Board of Directors
15 Jun 2023 //
PR NEWSWIRE
Jubilant`s Selective Demonstrates Activity in Rheumatoid Arthritis Models
13 Apr 2023 //
PR NEWSWIRE
Jubilant receives Orphan Drug Designation for the PRMT5 inhibitor
13 Feb 2023 //
PR NEWSWIRE
Jubilant receives FDA IND clearance for Phase I/II solid tumour trial
04 Aug 2022 //
CLINICALTRIALSARENA
Jubilant Tx announces US FDA clearance of IND for JBI-778 for solid tumors
03 Aug 2022 //
PRNEWSWIRE
Jubilant Tx Reports Development of Small Molecule Inhibitors of PD-L1 at ASCO
01 Jun 2022 //
PRNEWSWIRE
Jubilant Tx Begins Dosing in PI/II Trial of JBI-802 in advanced solid tumors
26 Apr 2022 //
PRNEWSWIRE
Jubilant Tx reports isoform-selective PAD4 inhibitors effect in tumors
11 Apr 2022 //
PRNEWSWIRE
Jubilant to present data on isoform selective PAD4 inhibitors to treat cancer
12 Mar 2022 //
PHARMABIZ
Jubilant to Present Data on Isoform Selective PAD4 inhibitors in Cancer at AACR
10 Mar 2022 //
PRNEWSWIRE
FDA Clears IND Enabling New Jersey-based Biotech to Launch Phase 1 Trial
09 Jan 2022 //
TRIALSITENEWS
FDA clears Jubilant Therapeutics’ IND for JBI-802 for treatment of solid tumours
08 Jan 2022 //
PHARMABIZ
FDA Clears Jubilant`s IND for JBI-802 for treatment of Solid Tumors
06 Jan 2022 //
PRNEWSWIRE
Jubilant Announces Successful Completion of Pre-IND Meeting with FDA
30 Sep 2021 //
PRNEWSWIRE
Jubilant Strengthens Board of Directors with Arrival of Leila Alland
17 Aug 2021 //
PRNEWSWIRE
Jubilant Strengthens Board of Directors with Addition of Leila Alland
16 Aug 2021 //
PR NEWSWIRE
Jubilant Pharma develops oral formulation of Remdesivir
20 Apr 2021 //
THEHINDU
Jubilant Pharma develops novel oral formulation of remdesivir
19 Apr 2021 //
BUSINESS-STANDARD
Jubilant Pharmova arm completes studies using novel oral formulation Remdesivir
19 Apr 2021 //
ECONOMIC TIMES
Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as CSO
08 Mar 2021 //
PRNEWSWIRE
Jubilant Announces Research Collaboration with Boston Children`s Hospital
26 Feb 2021 //
PRNEWSWIRE
Jubilant Announces Research Collaboration with Boston Childs Hospital
25 Feb 2021 //
PRNEWSWIRE
Jubilant and The Wistar Insitute collaborate on potential COVID-19 treatment
18 Jan 2021 //
PHARMAFILE
Jubilant Announces Research Collaboration with The Wistar Institute
15 Jan 2021 //
PRNEWSWIRE
Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH
07 Dec 2020 //
PRNEWSWIRE
Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH
07 Dec 2020 //
PRNEWSWIRE
Jubilant Therapeutics Announces Upcoming Presentation at 2020 ASH
24 Nov 2020 //
PRNEWSWIRE
Indian drug firms recall various products in US market
13 Nov 2020 //
TRIBUNEINDIA
Jubilant Therapeutics, OneThree Biotech collab to advance precision oncology
12 Nov 2020 //
PHARMABIZ
Jubilant and OneThree Biotech Collaborate to Advance Precision Oncology
12 Nov 2020 //
PRNEWSWIRE
Jubilant Biosys Limited announces the merger with Jubilant Chemsys Limited
27 Jul 2020 //
PRNEWSWIRE
Jubilant Life: New Covid drug, value unlocking potential to lead to upside
08 Jul 2020 //
BUSINESS-STANDARD
Mylan gets approval to make and market remdesivir
02 Jul 2020 //
EXPRESSPHARMA
